Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Pre-Market Mover With Heavy Volume Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Ironwood Pharmaceuticals ( IRWD) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Ironwood Pharmaceuticals as such a stock due to the following factors:

  • IRWD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $11.9 million.
  • IRWD traded 98,200 shares today in the pre-market hours as of 9:13 AM, representing 10% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in IRWD with the Ticky from Trade-Ideas. See the FREE profile for IRWD NOW at Trade-Ideas

More details on IRWD:

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. Currently there are 2 analysts that rate Ironwood Pharmaceuticals a buy, 1 analyst rates it a sell, and 6 rate it a hold.

The average volume for Ironwood Pharmaceuticals has been 956,100 shares per day over the past 30 days. Ironwood has a market cap of $1.8 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.11 and a short float of 18.7% with 13.88 days to cover. Shares are down 8% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

5 Ways Allergan Can Keep Up Momentum

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock